Central regions | Finance, business

Russia’s RVC publishes 19 exits in 2018

5 Feb '19
RVC, Russia’s national fund of funds for innovation, has unveiled its 2018 operation results. For example, last year the sovereign fund approved a total of $30.8m in investments for 30 portfolio companies, a 40% increase from its 2017 investments (which totaled $21.5m in 24 portfolio companies).

In 2018, RVC made 19 exits from their portfolio companies worth a total of $26m (from six the year before). In 18 of these, the government investor ended up in the black.

For example, in September 2018 RBV Capital, a VC fund set up jointly by RVC and R-Pharm, sold its portfolio company, botulinum toxin (BTX) developer Bonti, to Allergan, an Irish pharmaceutical giant. The Irish paid an initial amount of $195m.
Publish in Twitter
Write to Facebook
Google Buzz
Write to LiveJournal
Show in MM
Share MK
COMMENT ON THIS STORY
Find Related Content

Locations:

Tags: RBV Capital (2) / RVC (169) / exits (0) /

Latest News: Central regions
16 Apr '19 | Technology & innovation
11 Apr '19 | Finance, business
10 Apr '19 | Transport, logistics | Finance, business
8 Apr '19 | Finance, business | Technology & innovation
 

Feature stories

4 Apr '19
Russian scientists have come up with what they say is...
29 Jan '19
Russian biologists and biophysicists have developed...
2 Nov '18
Drawing upon in-depth interviews, the book channels...
Search (News archive - 21340)
Advertising
Venture_Russia_2018
Advertising
NATT
Advertising
Independent Software Developers Forum
Advertising
Marchmont News

Latest News

19 Apr '19
Scientists in Rostov-on-Don, in Russia’s Southwest...
18 Apr '19
Dsight, a Russian analytic company, has put together...
17 Apr '19
Scientists at the Far Eastern Federal University in...

Most read stories from last week

17 Apr '19
Scientists at the Far Eastern Federal University in...
19 Apr '19
Scientists in Rostov-on-Don, in Russia’s Southwest...
18 Apr '19
Dsight, a Russian analytic company, has put together...